此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Mean Platelet Volume (MPV) as an Early Predictor of Mortality in Intensive Care Patients With Cancer (MPV-CICU)

2026年8月31日 更新者:Eda Cennet Caferoğlu、Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
This study aims to investigate whether Mean Platelet Volume (MPV) and other blood count parameters measured at admission can predict mortality in cancer patients admitted to the intensive care unit (ICU). Patients with cancer are highly vulnerable to complications and organ failure, making early risk assessment vital for improving treatment strategies. Researchers will retrospectively review the medical charts and electronic health records of adult patients who stayed in the anesthesia ICU for longer than 24 hours between 2020 and 2025. No new laboratory tests, interventions, or patient contact will occur. The collected data will be analyzed to determine the relationship between initial MPV levels and patient survival outcomes.

研究概览

地位

完全的

详细说明

This retrospective, observational, single-center study will evaluate the predictive value of initial Mean Platelet Volume (MPV) and other hemogram parameters (such as Red Cell Distribution Width [RDW] and platelet count) on intensive care and hospital mortality. The primary objective is to investigate the correlation between these routinely measured, cost-effective biomarkers and survival outcomes in oncological critical care patients. The study hypotheses are structured as follows:

  • H0: There is no significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer.
  • H1: There is a significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer. Data regarding demographics (age, sex), clinical diagnoses, comorbidities, length of stay, APACHE II, SOFA scores, and laboratory parameters (CRP, procalcitonin) will be extracted from hospital electronic database records. All patient data will be anonymized before statistical analysis.

Note on Study Design: This study is designed as a retrospective cohort study. Due to system registry constraints in the protocol module, the time perspective has been specified as 'Other' (Retrospective Cohort).

研究类型

观察性的

注册 (实际的)

425

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Ankara、土耳其(türkiye)
        • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population consists of adult oncological patients who required critical care and were admitted to the anesthesia intensive care unit of a tertiary oncology training and research hospital between 2020 and 2025.

描述

Inclusion Criteria:

  • Adult patients aged 18 years and older.
  • Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies).
  • Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025.
  • Patients with an ICU length of stay longer than 24 hours.
  • Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission.

Exclusion Criteria:

  • Patients under the age of 18.
  • Patients who stayed in the intensive care unit for less than 24 hours.
  • Patients with missing or incomplete medical charts, laboratory data, or survival status records.
  • Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated).
  • Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Oncological ICU Patients
Adult patients (aged 18 and older) with a confirmed cancer diagnosis who were admitted to the anesthesia intensive care unit for longer than 24 hours between the years 2020 and 2025

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Intensive Care Unit (ICU) Mortality
大体时间:From the date of ICU admission up to ICU discharge, assessed up to 30 days.
The percentage of oncological patients who died during their stay in the anesthesia intensive care unit. This will be calculated based on the electronic health records and patient files.
From the date of ICU admission up to ICU discharge, assessed up to 30 days.

次要结果测量

结果测量
措施说明
大体时间
Hospital Mortality
大体时间:From the date of hospital admission up to hospital discharge, assessed up to 60 days.
The percentage of oncological patients who died during their overall hospital stay (including post-ICU ward follow-up).
From the date of hospital admission up to hospital discharge, assessed up to 60 days.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月15日

初级完成 (实际的)

2026年8月1日

研究完成 (实际的)

2026年8月1日

研究注册日期

首次提交

2026年6月15日

首先提交符合 QC 标准的

2026年6月15日

首次发布 (实际的)

2026年6月18日

研究记录更新

最后更新发布 (实际的)

2026年9月2日

上次提交的符合 QC 标准的更新

2026年8月31日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared globally to maintain patient confidentiality and privacy in accordance with local data protection regulations and institutional review board restrictions. However, the coded datasets and statistical analyses used during the current study may be available from the corresponding author upon reasonable academic request.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅